Treatment of postmenopausal osteoporosis, patient perspectives - Focus on once yearly zoledronic acid

Patient Preference and Adherence

Volumn 3, Issue , 2009, Pages 189-193

  Carmona, Raj ^a   Adachi, Rick ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Bisphosphonate; Fractures; Osteoporosis; Zoledronic acid

Indexed keywords

EID: 79959795571     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S3494     Document Type: Review

References (21)

1. National Osteoporosis Foundation. Disease Statistics. Available online at http://www.nof.org/osteoporosis/diseasefacts.htm. Accessed April 15, 2009.
2. Cooper C, Campion G, Melton L. Hip fracture in the elderly: A worldwide projection. Osteoporosis Int. 1992;48:285-289.
3. Fink H, Ensrud K, Nelson D, Kerani R, Schreiner P, Zhao Y, et al. Disability after clinical fracture in postmenopausal women with low bone density: the fracture intervention trial (FIT). Osteoporosis Int. 2003;14:69-76.
4. Mazanec D. Osteoporosis screening: time to take responsibility. Arch Intern Med. 2004;164:1047-1048.
5. Recker R, Gallagher R, MacCosbe P. Effect of dosing frequency on bisphosphonates medication adherence in a large longitudinal cohort of women. Mayo Clin Proc. 2005;80:856-861.
6. Gallagher A, Rietbrock S, Olson M, Van Staa T. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res. 2008;23:1569-1575.
7. Huybrechts K, Ishak K, Caro J. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006;38:922-928.
8. Siris E, Harris S, Rosen C, Barr C, Arvesen J, Abbott T, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81:1013-1022.
9. Badamgarav E, Fitzpatrick L. A new look at osteoporosis outcomes: the influence of treatment, compliance, persistence, and adherence. Mayo Clin Proc. 2006;81:1009-1012.
10. Cramer J, Gold D, Silverman S, Lewiecki E. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporosis Int. 2007;18:1023-1031.
11. Reginster J, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone. 2006; 38(4 Suppl 1):S2-S6.
12. Solomon D, Avorn J, Katz J, Finkelstein J, Arnold M, Polinski J, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005;165:2414-1419.
13. Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W. A single Zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone. 2007;40:1238-1243.
14. McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, et al. Intravenous Zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone. 2007;41:122-128.
15. Green J, Muller K, Jaeggi K. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994;9:745-751.
16. Novartis Pharmaceuticals Canada Inc. Aclasta product monograph. June 2005 (revised March 2009).
17. Black D, Delmas P, Eastell R, Reid I, Boonen S, Cauley J, et al. Onceyearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-1822.
18. Lyles K, Colon-Emeric C, Magaziner J, Adachi J, Pieper C, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Eng J Med. 2007;357:1799-1809.
19. U.S. Food and Drug Administration. Update of safety review to the October 1, 2007 early communication about the ongoing safety review of bisphosphonates. Nov 12, 2008. Available online at http://www. fda.gov/cder/drug/early_comm/bisphosphonates_update_200811.htm. Accessed April 15, 2009.
20. Khosla S, Burr D, Cauley J, Dempster D, Ebeling P, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task forceof the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479-1491.
21. Fraenkel L, Gulanski B, Wittink D. Patient treatment preferences for osteoporosis. Arth Rheum. 2006;55:729-735.